SHTDF — Sinopharm Co Income Statement
0.000.00%
Last trade - 00:00
- $8.24bn
- $22.62bn
- CNY552.15bn
- 85
- 97
- 65
- 96
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 344,526 | 425,273 | 456,415 | 521,051 | 552,148 |
Cost of Revenue | |||||
Gross Profit | 31,228 | 37,531 | 40,323 | 44,051 | 47,434 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 329,129 | 409,250 | 438,788 | 501,949 | 531,605 |
Operating Profit | 15,397 | 16,023 | 17,626 | 19,103 | 20,543 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 12,208 | 13,760 | 15,598 | 17,003 | 18,564 |
Provision for Income Taxes | |||||
Net Income After Taxes | 9,404 | 10,620 | 12,097 | 13,065 | 14,345 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 5,836 | 6,253 | 7,187 | 7,759 | 8,526 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 5,834 | 6,251 | 7,187 | 7,759 | 8,526 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.05 | 2.13 | 2.33 | 2.62 | 2.74 |
Dividends per Share |